• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.泰利霉素对具有23S rRNA突变及核糖体蛋白L4和L22改变的大环内酯类耐药肺炎链球菌分离株活性的时间杀菌研究
Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3. doi: 10.1128/AAC.49.7.3011-3013.2005.
2
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.两种新型大环内酯类药物GW 773546和GW 708408与红霉素、阿奇霉素、克拉霉素、克林霉素和泰利霉素相比的抗肺炎球菌活性。
Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12. doi: 10.1128/AAC.48.11.4103-4112.2004.
3
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.两种新型大环内酯类药物GW 773546和GW 708408与泰利霉素、红霉素、阿奇霉素及克拉霉素相比，对流感嗜血杆菌的抗菌活性。
Antimicrob Agents Chemother. 2004 Nov;48(11):4113-9. doi: 10.1128/AAC.48.11.4113-4119.2004.
4
Mechanisms of resistance to telithromycin in Streptococcus pneumoniae.肺炎链球菌对泰利霉素的耐药机制
J Antimicrob Chemother. 2005 Sep;56(3):447-50. doi: 10.1093/jac/dki249. Epub 2005 Jul 8.
5
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.泰利霉素、利奈唑胺和奎奴普丁-达福普汀对因核糖体突变而对大环内酯类耐药的肺炎链球菌的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3169-71. doi: 10.1128/AAC.48.8.3169-3171.2004.
6
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.肺炎链球菌中赋予对大环内酯类、克林霉素、链阳菌素和替利霉素耐药性的核糖体突变的多样性。
Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.
7
Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology.利用体外时间杀菌方法评估泰利霉素对具有核糖体突变的肺炎链球菌的作用。
Int J Antimicrob Agents. 2005 Oct;26(4):331-4. doi: 10.1016/j.ijantimicag.2005.07.013.
8
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).在加拿大呼吸道病原体药敏试验（CROSS，1998 - 2004年）的6年期间分离出的肺炎链球菌中的大环内酯类耐药机制。
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
9
High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.肺炎链球菌实验室诱导突变体中的高水平替利霉素耐药性。
J Antimicrob Chemother. 2003 Sep;52(3):345-53. doi: 10.1093/jac/dkg348. Epub 2003 Aug 13.
10
Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.模拟临床可达到的游离血清和上皮衬液浓度时，泰利霉素对大环内酯类敏感和耐药肺炎链球菌的药效学活性。
J Antimicrob Chemother. 2004 Dec;54(6):1072-7. doi: 10.1093/jac/dkh475. Epub 2004 Nov 5.

引用本文的文献

1
Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.酮内酯类——大环内酯类的现代衍生物：药代动力学视角
Clin Pharmacokinet. 2009;48(1):23-38. doi: 10.2165/0003088-200948010-00002.

本文引用的文献

1
In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.含新型2-氟萘啶的酮内酯类化合物的体外活性
Antimicrob Agents Chemother. 2005 Jan;49(1):309-15. doi: 10.1128/AAC.49.1.309-315.2005.
2
Activity of telithromycin against erythromycin-susceptible and -resistant Streptococcus pneumoniae isolates from adults with invasive infections.泰利霉素对侵袭性感染成年患者中对红霉素敏感及耐药的肺炎链球菌分离株的活性。
Int J Antimicrob Agents. 2004 Dec;24(6):616-8. doi: 10.1016/j.ijantimicag.2004.06.018.
3
Clinical efficacy of ketolides in the treatment of respiratory tract infections.酮内酯类药物治疗呼吸道感染的临床疗效
J Antimicrob Chemother. 2004 Jun;53(6):918-27. doi: 10.1093/jac/dkh169. Epub 2004 Apr 29.
4
Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.在德国分离出的肺炎链球菌临床菌株中赋予对大环内酯类抗生素耐药性的核糖体突变。
Antimicrob Agents Chemother. 2003 Jul;47(7):2319-22. doi: 10.1128/AAC.47.7.2319-2322.2003.
5
Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.2000 - 2001年德国儿科人群中对大环内酯类耐药的肺炎链球菌和化脓性链球菌
Antimicrob Agents Chemother. 2003 Feb;47(2):489-93. doi: 10.1128/AAC.47.2.489-493.2003.
6
Emergence of macrolide resistance during treatment of pneumococcal pneumonia.肺炎球菌肺炎治疗期间大环内酯类耐药性的出现。
N Engl J Med. 2002 Feb 21;346(8):630-1. doi: 10.1056/NEJM200202213460820.
7
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.来自10个中东欧国家的992株肺炎球菌对泰利霉素和其他六种药物的敏感性以及因L4核糖体蛋白突变导致的大环内酯类耐药性流行情况。
Antimicrob Agents Chemother. 2002 Feb;46(2):371-7. doi: 10.1128/AAC.46.2.371-377.2002.
8
Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.德国侵袭性肺炎球菌分离株中大环内酯类和青霉素耐药性的出现。
J Antimicrob Chemother. 2002 Jan;49(1):61-8. doi: 10.1093/jac/49.1.61.
9
Macrolide resistance among invasive Streptococcus pneumoniae isolates.侵袭性肺炎链球菌分离株中的大环内酯类耐药性
JAMA. 2001 Oct 17;286(15):1857-62. doi: 10.1001/jama.286.15.1857.
10
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.23S核糖体RNA和核糖体蛋白L4中的突变导致了在体外经大环内酯类药物传代筛选出的肺炎球菌菌株产生耐药性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2118-25. doi: 10.1128/AAC.44.8.2118-2125.2000.

泰利霉素对具有23S rRNA突变及核糖体蛋白L4和L22改变的大环内酯类耐药肺炎链球菌分离株活性的时间杀菌研究

Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.

作者信息

Reinert Ralf René, Al-Lahham Adnan

机构信息

Institute of Medical Microbiology, National Reference Centre for Streptococci, University of Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany.

出版信息

Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3. doi: 10.1128/AAC.49.7.3011-3013.2005.

DOI:10.1128/AAC.49.7.3011-3013.2005
PMID:15980387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1168645/
Abstract

By use of a time-kill methodology, the antipneumococcal activity of telithromycin was determined against macrolide-resistant S. pneumoniae isolates having mutations in the 23S rRNA gene and changes in the ribosomal proteins L4 and L22. Telithromycin had MICs ranging between 0.03 and 0.25 microg/ml and was bactericidal against four of seven strains after 24 h at two times the MIC.

摘要

通过时间杀菌方法，测定了泰利霉素对23S rRNA基因发生突变以及核糖体蛋白L4和L22发生改变的大环内酯类耐药肺炎链球菌分离株的抗肺炎链球菌活性。泰利霉素的最低抑菌浓度（MIC）范围为0.03至0.25微克/毫升，在两倍MIC浓度下作用24小时后，对七株菌株中的四株具有杀菌作用。